Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2012

Heinrich Michael C, Griffith Diana, McKinley Arin, Patterson Janice, Presnell Ajia, Ramachandran Abhijit, Debiec-Rychter Maria

Abstract excerpt

PURPOSE: To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA. EXPERIMENTAL DESIGN: The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kinases expressed in several different cell line models, including primary gastrointestinal stromal tumors (GIST) cells. The antiproliferative activity of crenolanib was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Inhibitory Concentration 50

Share to Piperazines

Share to Piperidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 22745105
DOI: 10.1158/1078-0432.CCR-12-0625

Genes

PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.PMID 22745105Read ↗

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.Semantic proximity Read ↗

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.Semantic proximity Read ↗

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.Semantic proximity Read ↗

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Semantic proximity Read ↗

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumorsSemantic proximity Read ↗

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.